Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Chiron Charts. Click Here for more Chiron Charts.](/p.php?pid=staticchart&s=N%5ECHIR&p=8&t=15)
Chiron Corporation (NASDAQ:CHIR) today announced that on
February 6, 2006, the European Commission adopted a decision pursuant
to Article 6(1)(b) of the Council Regulation (EC) No. 139/2004
declaring the combination compatible with the common market. This
follows approval by the U.S. Federal Trade Commission (FTC) in
December 2005 and clearance by the Committee on Foreign Investment in
the United States (CFIUS) under Exon-Florio in January 2006.
Subject to stockholder approval and other customary conditions,
Chiron and Novartis expect that this transaction will be completed in
the first half of 2006.
About Chiron
Chiron delivers innovative and valuable products to protect human
health by advancing pioneering science across the landscape of
biotechnology. The company works to deliver on the limitless promise
of science and make a positive difference in people's lives. For more
information, please visit www.chiron.com.
This news release contains forward-looking statements that involve
risks and uncertainties and are subject to change. In particular,
there can be no guarantee that the transaction contemplated by the
merger agreement will be consummated. A discussion of the company's
operations and financial condition, including factors that may affect
its business and future prospects that could cause actual results and
developments to differ materially from those expressed or implied by
any forward-looking statements, is contained in documents the company
has filed with the SEC, including the Form 10-K for the year ended
December 31, 2004, and the Form 10-Q for the quarter ended September
30, 2005, and will be contained in all subsequent periodic filings
made with the SEC. These documents identify important factors that
could cause the company's actual performance to differ from current
expectations.
Chiron does not undertake an obligation to update the
forward-looking information the company is giving today.
RULE 14a-12 LEGEND
Participants in Solicitation
Chiron Corporation and Novartis AG and their respective directors
and officers may be deemed to be participants in the solicitation of
proxies from Chiron shareholders in connection with the merger.
Information about the directors and executive officers of Chiron and
their ownership of Chiron's stock is set forth in the proxy statement
for Chiron's 2005 Annual Meeting of Shareholders.
Investors can obtain more information when the Schedule 13e-3 and
the proxy statement become available. Investors should read the
Schedule 13e-3 and proxy statement carefully when they become
available before making any voting decision.